We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Daniel Spratt

Daniel E. Spratt MD

Vice Chair, Clinical Research; Chair, Genitourinary Division for Clinical Research; Assistant Professor, Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan

Dan Spratt, MD, is a tenured Full Professor of Radiation Oncology and a leader in Prostate and Spine malignancies. In addition to his medical training at Vanderbilt University where he obtained his medical degree, he completed his Radiation Oncology Residency at Memorial Sloan Kettering Cancer Center.  In the Department of Radiation Oncology, Dr. Spratt is the Chief of the Genitourinary Radiotherapy Program, Associate Chair of Clinical Research, and the Laurie Snow Endowed Research Professor.  In the Rogel Cancer Center he is the co-Chair of the Genitourinary Clinical Research Team and co-Director of the Spine Oncology Program.  He holds leadership positons in the NIH U-10 LAPS cooperative group trial efforts and Prostate Cancer SPORE.  He is the head of the Intact Prostate Cancer Subcommittee within the NRG Genitourinary Core Committee for national clinical trials, and a committee member for the NCCN Prostate Cancer national guidelines.

Dr. Spratt has received funding from the National Institutes of Health, Department of Defense, and multiple other funding bodies and foundations for his research.  He has published over 275 papers primarily on the topics of prostate cancer and prognostic and predictive biomarkers.  He has developed widely used clinical and clinicogenomic models for prostate cancer, multiple of which are cited in the National Comprehensive Cancer Network (NCCN) guidelines.  He is the PI of numerous prostate cancer clinical trials including as co-PI of the multinational randomized phase II BALANCE trial (NRG GU006), North-American PI of the STAMPEDE Arm M phase III trial, national PI of the ASCLEPIUS multicenter phase I/II trial, and multi-center co-PI for G-MAJOR randomized phase III trial. His laboratory focuses on the interaction of androgen signaling and DNA repair in prostate cancer and methods to overcome radiation resistance.

Disclosures

Dr. Spratt reports the following:
  • Personal fees: Janssen, AstraZeneca, Blue Earth, Boston Scientific
  • Funding, Janssen